empty
 
 
gr
Αναζήτηση
Υποστήριξη
Άμεσο άνοιγμα λογαριασμού
Πλατφόρμα συναλλαγών
Κατάθεση/Ανάληψη
Αναζήτηση
Για αρχάριους Για επενδυτές Για Συνεργάτες Κάντε ένα διάλειμμα Σχετικά με την InstaSpot
gr
#ACB Return to the list of instruments #AMGN

Currency converter

Alnylam Pharmaceuticals Inc.
398.32 USD
12 Dec 2025 22:59
Price Change (% chg)
$1.76
(0.44%)
Prev Close
Prev Close

Closing price, the previous day.
$412.09
Open
Open

Opening price.
$404.18
Day's High
Day's High

The highest price over the last trading day.
$409.79
Day's Low
Day's Low

The lowest price over the last trading day
$386.11
Week High
Week High

Price range high in the last week
$476.29
Week Low
Week Low

Price range low in the last week
$386.11
Download archive
Buy
398.32
Sell
398.32
Open the chart in full screen view
Buy
398.32
Sell
398.32
Download archive
Open the chart in full screen view

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

  • The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
  • The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
  • Constantly growing revenues are the firm’s advantage;
  • Enough own funds to finance projects without the need to additionally issue securities.

Can't speak right now?
Ask your question in the chat.